Anastrozole was patented in 1987 and approved for medical use in 1995. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e., following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.

SynZeal Research offers all Anastrozole related impurities which certified COA with all characterization data like IR, Mass, HPLC purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Anastrozole related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.